- Home
- HWBK vs VNDA Comparison
HWBK vs VNDA Comparison
Compare HWBK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWBK
- VNDA
- Stock Information
- Founded
- HWBK 1865
- VNDA 2002
- Country
- HWBK United States
- VNDA United States
- Employees
- HWBK N/A
- VNDA N/A
- Industry
- HWBK Major Banks
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- HWBK Finance
- VNDA Health Care
- Exchange
- HWBK Nasdaq
- VNDA Nasdaq
- Market Cap
- HWBK 218.6M
- VNDA 249.4M
- IPO Year
- HWBK N/A
- VNDA 2006
- Fundamental
- Price
- HWBK $29.67
- VNDA $5.33
- Analyst Decision
- HWBK
- VNDA Strong Buy
- Analyst Count
- HWBK 0
- VNDA 2
- Target Price
- HWBK N/A
- VNDA $16.50
- AVG Volume (30 Days)
- HWBK 8.3K
- VNDA 495.7K
- Earning Date
- HWBK 10-29-2025
- VNDA 11-05-2025
- Dividend Yield
- HWBK 2.70%
- VNDA N/A
- EPS Growth
- HWBK 396.63
- VNDA N/A
- EPS
- HWBK 2.96
- VNDA N/A
- Revenue
- HWBK $75,021,000.00
- VNDA $203,467,000.00
- Revenue This Year
- HWBK N/A
- VNDA $15.45
- Revenue Next Year
- HWBK N/A
- VNDA $37.82
- P/E Ratio
- HWBK $10.05
- VNDA N/A
- Revenue Growth
- HWBK 33.44
- VNDA 11.78
- 52 Week Low
- HWBK $21.73
- VNDA $3.81
- 52 Week High
- HWBK $35.95
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- HWBK 40.93
- VNDA 66.70
- Support Level
- HWBK $29.64
- VNDA $4.84
- Resistance Level
- HWBK $31.76
- VNDA $5.48
- Average True Range (ATR)
- HWBK 0.75
- VNDA 0.21
- MACD
- HWBK -0.25
- VNDA 0.07
- Stochastic Oscillator
- HWBK 4.11
- VNDA 86.57
About HWBK Hawthorn Bancshares Inc.
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.